ImPact Biotech

Company Overview

Snapshot

Founded in January 1996, ImPact Biotech operates with 11–50 employees, focusing on advanced oncology treatments. The company has raised $2.7 million across one funding round. In July 2024, ImPact Biotech secured a grant from the European Innovation Council, highlighting ongoing support for its innovative therapeutic approaches.

Business overview

ImPact Biotech is a biotechnology company dedicated to developing and commercializing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy. This novel oncology technology platform delivers an inactive drug, Padeliporfin, which is activated precisely within the tumor micro-environment by non-thermal laser light. This mechanism leads to the occlusion of the tumor's blood supply and immunogenic cell death, minimizing impact on healthy surrounding tissues. The company holds exclusive rights from the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center for VTP development and commercialization, serving the pharmaceutical and healthcare sectors with solutions in cancer therapy and drug development.

Strategic signal

In September 2024, ImPact Biotech announced 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial for Padeliporfin VTP in low-grade upper tract urothelial cancer. This milestone indicates significant progress in the clinical development of its lead therapeutic candidate, suggesting a strong operational trajectory and potential for future market entry in a critical oncology area.

Company Intelligence Q&A

What is ImPact Biotech's core technology?

ImPact Biotech's core technology is Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, which involves the intravenous delivery of an inactive drug, Padeliporfin, activated by non-thermal laser light directly in the tumor micro-environment for selective tumor ablation.

When did ImPact Biotech achieve 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial?

In September 2024, ImPact Biotech announced 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP for low-grade upper tract urothelial cancer.

Has ImPact Biotech received any regulatory designations for its cancer therapy?

In July 2023, the FDA granted orphan drug designation to ImPact Biotech's focal cancer therapy, acknowledging its potential to address rare conditions.

What was the outcome of ImPact Biotech's IND application for Padeliporfin VTP in pancreatic cancer?

In December 2023, ImPact Biotech received FDA clearance of its Investigational New Drug (IND) application for Padeliporfin VTP in pancreatic cancer, allowing clinical trials to proceed for this indication.

What was the most recent funding event for ImPact Biotech?

In July 2024, ImPact Biotech secured a grant from the European Innovation Council.